

RANBAXY LABORATORIES LIMITED
Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2013
(Rupees in millions, except share data, per share data and if otherwise stated)

Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
		Quarter ended 30 June	Quarter ended 31 March	Quarter ended 30 June	Six months ended 30 June	2012	Year ended 31 December
		2013	2013	2012	2013	2012	2012
1	Income from operations						
	(a) Sales						
	- Within India (net of excise duty)	5,577.90	5,629.10	5,612.24	11,207.00	10,657.34	22,031.54
	- Outside India (refer to note 1)	8,373.06	7,649.67	9,115.26	16,022.73	22,172.44	39,092.89
	Net sales (net of excise duty)	13,950.96	13,278.77	14,727.50	27,229.73	32,829.78	61,124.43
	(b) Other operating income	437.90	537.59	531.48	975.49	1,093.92	1,911.01
	Total income from operations (net)	14,388.86	13,816.36	15,258.98	28,205.22	33,923.70	63,035.44
2	Expenses						
	(a) Cost of materials consumed	4,016.13	4,086.05	3,792.30	8,102.18	7,430.49	15,286.61
	(b) Purchases of stock-in-trade	1,635.87	1,906.89	2,152.94	3,542.76	4,092.96	8,090.01
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (refer to note 3)	141.52	(392.07)	(182.53)	(250.55)	(73.09)	(492.45)
	(d) Employee benefits expense (refer to note 4)	2,630.74	2,458.01	2,531.68	5,088.75	5,047.96	10,195.89
	(e) Depreciation, amortisation and impairment expense	446.45	452.93	485.34	899.38	954.07	1,861.61
	(f) Claims and contractual expense (refer to note 3)	99.54	22.64	897.11	122.18	3,142.03	3,842.89
	(g) Other expenses	5,459.19	5,319.12	4,796.06	10,778.31	9,385.96	20,118.78
	(h) Foreign exchange loss (others), net	1,913.67	96.96	3,027.87	2,010.63	1,728.37	1,388.84
	Total expenses	16,343.11	13,950.53	17,500.77	30,293.64	31,708.75	60,292.18
3	(Loss)/ profit from operations before other income, finance costs and exceptional items (1-2)	(1,954.25)	(134.17)	(2,241.79)	(2,088.42)	2,214.95	2,743.26
4	Other income	310.43	523.26	610.88	833.69	1,147.79	2,395.98
5	(Loss)/ profit from ordinary activities before finance costs and exceptional items (3+4)	(1,643.82)	389.09	(1,630.91)	(1,254.73)	3,362.74	5,139.24
6	Finance costs (refer to note 11)	1,561.27	506.04	1,632.23	2,067.31	1,800.73	2,969.82
7	(Loss)/ profit from ordinary activities after finance costs but before exceptional items (5-6)	(3,205.09)	(116.95)	(3,263.14)	(3,322.04)	1,562.01	2,169.42
8	Exceptional items						
	- Settlement provision reversal (refer to note 2)	1,458.05	-	-	1,458.05	-	-
	- (Loss)/ gain on foreign currency option derivatives, net (other than loans) (refer to note 5)	(3,671.03)	818.42	(5,993.52)	(2,852.61)	(2,546.36)	(412.05)
	- Product recall	-	-	-	-	-	(2,370.20)
	- Provision for other-than-temporary diminution in the value of non-current investment in a subsidiary	(670.02)	-	-	(670.02)	-	(1,030.00)
9	(Loss)/ profit from ordinary activities before tax (7+8)	(6,088.09)	701.47	(9,256.66)	(5,386.62)	(984.35)	(1,642.83)
10	Tax benefit, net	-	-	-	-	-	(19.44)
11	Net (loss)/ profit for the period (9-10)	(6,088.09)	701.47	(9,256.66)	(5,386.62)	(984.35)	(1,623.39)
12	Paid - up equity share capital (Face value of Rs. 5 each)	2,115.50	2,115.03	2,110.56	2,115.50	2,110.56	2,114.57
13	Reserves excluding Revaluation Reserves as per Balance Sheet						17,095.10
14	(Loss)/ earnings per share (Rs.) - not annualised						
	Basic	(14.40)	1.66	(21.95)	(12.74)	(2.33)	(3.85)
	Diluted	(14.40)	1.66	(21.95)	(12.74)	(2.33)	(3.85)
15	Debt service coverage ratio (refer to note 7)				(0.60)		0.08
16	Interest service coverage ratio (refer to note 7)				(1.61)		0.45

See accompanying notes to the standalone unaudited financial results

PART II							
Select information for the quarter and six months ended 30 June 2013							
Sr. No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Six months ended		
		30 June	31 March	30 June	30 June	2012	Year ended 31 December
		2013	2013	2012	2013	2012	2012
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding #						
	- Number of shares	145,679,333	145,437,363	145,005,743	145,679,333	145,005,743	145,239,372
	- Percentage of shareholding	34.43%	34.38%	34.35%	34.43%	34.35%	34.34%
2	Promoters and promoter group shareholding						
	a) Pledged / encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non - encumbered						
	- Number of shares	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323	268,711,323
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	63.51%	63.52%	63.66%	63.51%	63.66%	63.54%

Aggregate public shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters and Promoter Group Shareholding and Global Depository Shares)

PART III		Quarter ended 30 June 2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed off during the quarter	2
	Remaining unresolved at the end of the quarter	Nil

RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2013

(Rupees in millions, except share data, per share data and if otherwise stated)

Notes:

- 1 Sales outside India include significant sales relating to First-To-File (FTF) products in the United States of America ("USA"). Further, pursuant to the accounting policy followed by the Company, sales outside India for all periods presented include transfer pricing adjustments with its subsidiaries for materials already supplied to them (including supplied in earlier periods), determined on the basis of significant judgment and estimates.
- 2 The Company has negotiated and settled with the Department of Justice ("DOJ") of the USA for resolution of civil and criminal allegations on 13 May 2013 as per the decree of the court of Maryland. The Company had recorded a provision of Rs. 26,480 (USD 500 million) in the year ended 31 December 2011, to cover all civil and criminal liability. The settlement of this liability (along with related interest and other cost) in compliance with the terms of settlement is subject to regulatory /statutory provisions. The abovementioned decretal amount of liability has been paid by the Company's US subsidiaries including Ranbaxy Pharmaceuticals Inc. (RPI), USA, a limited risk distributor. Under the said agreement of distribution, RPI has invoked indemnity for itself and inter alia its affiliates. The settlement amount has accordingly been apportioned between the Company and its US subsidiaries. The resultant accounting adjustment for reversal of earlier provision to the extent of apportionment to the US subsidiaries amounting to Rs.1,458.05 (USD 26.1 million) has been disclosed as an exceptional item in the accompanying financial results for the quarter and six months ended 30 June 2013.
- 3 Changes in inventories of finished goods, work-in-progress and stock-in-trade for the six months period ended 30 June 2013 and Claims and contractual expense for the quarter ended 30 June 2013 include prior period adjustment of Rs. 113.51 and Rs. 55.09 respectively .
- 4 Employee benefits expense for the six months period ended 30 June 2013 is net of Rs. 304.58 representing impact of revision in a defined benefit plan applicable to certain employees of the Company.
- 5 The amount represents foreign exchange (loss)/ gain, net, on foreign currency option derivatives taken during previous years (other than option derivatives relating to loans) which are accounted in accordance with Accounting Standard 30, "Financial Instruments: Recognition and Measurement".
- 6 Standalone Statement of Assets and Liabilities are given below:

Particulars	(Unaudited) As at 30 June 2013	(Audited) As at 31 December 2012
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
a) Share capital	2,115.50	2,114.57
b) Reserves and surplus	11,904.10	17,095.10
Sub-total - Shareholders' funds	14,019.60	19,209.67
2 Share application money pending allotment	3.94	11.10
3 Non-current liabilities		
a) Long-term borrowings	25,313.77	19,568.10
b) Other long-term liabilities	9,244.97	10,363.48
c) Long-term provisions	1,485.68	2,739.04
Sub-total - Non-current liabilities	36,044.42	32,670.62
4 Current liabilities		
a) Short-term borrowings	31,071.50	28,067.95
b) Trade payables	9,324.85	8,588.11
c) Other current liabilities	41,684.35	13,320.78
d) Short-term provisions	395.59	27,831.11
Sub-total - Current liabilities	82,476.29	77,807.95
TOTAL EQUITY AND LIABILITIES	132,544.25	129,699.34
B ASSETS		
1 Non-current assets		
a) Fixed assets	21,933.95	21,531.24
b) Non-current investments (refer to note 12)	30,611.36	31,281.37
c) Deferred tax assets (net)	-	-
d) Long-term loans and advances	21,357.41	10,107.12
e) Other non-current assets	1,386.90	215.70
Sub-total - Non-current assets	75,289.62	63,135.43
2 Current assets		
a) Current investments	23.80	30.32
b) Inventories	17,755.08	17,318.39
c) Trade receivables	15,324.64	14,358.88
d) Cash and cash equivalents #	9,153.02	28,347.73
e) Short-term loans and advances	12,873.38	5,041.48
f) Other current assets	2,124.71	1,467.11
Sub-total - Current assets	57,254.63	66,563.91
TOTAL ASSETS	132,544.25	129,699.34

include Rs. 8,819.88 (Rs.27,682.02 as at 31 December 2012) represented by "other bank balances" which are due for realisation within twelve months from the reporting date and unclaimed dividend accounts.

RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 June 2013

(Rupees in millions, except share data, per share data and if otherwise stated)

Notes:

- 7 Due to issuance of debentures in November 2012, certain required ratios have been presented. The ratios have been computed as below:
 Debt service coverage ratio = Earnings before Interest and Tax/ (Interest expense for the period + Principal Repayment for all the loan funds during the period).
 Interest service coverage ratio = Earnings before Interest and Tax/ Interest expense for the period.
 Earning before Interest and Tax = Earnings from ordinary activity before tax (serial no. 9) + Finance costs (serial no. 6)
- 8 The research and development expenses is classified under respective heads of total expenses according to the nature of expense. The aggregate amount of such expenses (excluding finance costs, depreciation, amortisation and impairment) for all periods presented is set out below:


Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	Quarter ended 30 June	Quarter ended 31 March	Quarter ended 30 June	Six months ended 30 June		Year ended 31 December
	2013	2013	2012	2013	2012	2012
Research and development expenses	1,051.60	1,020.19	1,156.31	2,071.79	2,173.40	4,490.41

- 9 On exercise of Employees Stock Options, 28,520 equity shares have been allotted on 10 July 2013. The total number of Employees Stock Options outstanding as at 30 June 2013 were 6,393,085, out of which 4,361,231 have vested. The entitlement of shares on exercise of stock options granted on or before 3 October 2002 would increase in the proportion of 3:5, keeping in view the issue of bonus shares on 11 October 2002.
- 10 The Company's business activity falls within a single primary business segment viz. 'Pharmaceutical'.
- 11 Finance costs include exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs. The aggregate amount of such exchange difference for all periods presented is set out below:

Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	Quarter ended 30 June	Quarter ended 31 March	Quarter ended 30 June	Six months ended 30 June		Year ended 31 December
	2013	2013	2012	2013	2012	2012
Foreign exchange loss	1,103.95	12.70	1,165.41	1,116.65	975.13	1,239.74

- 12 With the receipt of all requisite approvals and filing of the returns with the respective Registrar of Companies, the Company's five wholly owned Indian subsidiaries viz. Ranbaxy Drugs and Chemicals Company, Ranbaxy SEZ Limited, Ranbaxy Life Sciences Research Limited, Solus Pharmaceuticals Limited and Rexcel Pharmaceuticals Limited, have merged with Ranbaxy Drugs Limited, another wholly owned subsidiary of the Company, effective 9 May 2013.
- 13 Previous periods figures have been reclassified to conform to the current period's classification.
- 14 The above results were reviewed by the Audit Committee on 6 August 2013, and approved by the Board of Directors at their meeting held on 7 August 2013 and have undergone a "Limited Review" by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the Bombay Stock Exchange and the National Stock Exchange and is also available on the Company's website at www.ranbaxy.com.

By order of the Board


 Arun Sawhney
 CEO and Managing Director

Place: Moscow, Russia
 Date: 7 August 2013

Regd. Office : A-41, Industrial Area Phase VIII A, Sahibzada Ajit Singh Nagar (Mohali) - 160 071 (Punjab)
 Website: <http://www.ranbaxy.com>